145 related articles for article (PubMed ID: 36723821)
21. DNA damage repair in ovarian cancer: unlocking the heterogeneity.
Gee ME; Faraahi Z; McCormick A; Edmondson RJ
J Ovarian Res; 2018 Jun; 11(1):50. PubMed ID: 29925418
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
23. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer.
Su D; Xu H; Feng J; Gao Y; Gu L; Ying L; Katsaros D; Yu H; Xu S; Qi M
J Transl Med; 2012 Feb; 10():31. PubMed ID: 22369209
[TBL] [Abstract][Full Text] [Related]
24. Location of the multimerin 1 binding site in coagulation factor V: an update.
Jeimy SB; Quinn-Allen MA; Fuller N; Kane WH; Hayward CP
Thromb Res; 2008; 123(2):352-4. PubMed ID: 18452976
[TBL] [Abstract][Full Text] [Related]
25. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.
Mirza-Aghazadeh-Attari M; Ostadian C; Saei AA; Mihanfar A; Darband SG; Sadighparvar S; Kaviani M; Samadi Kafil H; Yousefi B; Majidinia M
DNA Repair (Amst); 2019 Aug; 80():59-84. PubMed ID: 31279973
[TBL] [Abstract][Full Text] [Related]
26. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
27. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
28. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
[TBL] [Abstract][Full Text] [Related]
29. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
[TBL] [Abstract][Full Text] [Related]
30. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
Ziebarth AJ; Nowsheen S; Steg AD; Shah MM; Katre AA; Dobbin ZC; Han HD; Lopez-Berestein G; Sood AK; Conner M; Yang ES; Landen CN
Clin Cancer Res; 2013 Jan; 19(1):170-82. PubMed ID: 23147994
[TBL] [Abstract][Full Text] [Related]
31. Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer.
Sengupta D; Mukhopadhyay A; Sengupta K
Biochem Soc Trans; 2020 Oct; 48(5):2317-2333. PubMed ID: 33084906
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of long intergenic noncoding RNA 01296 in ovarian cancer impacts invasion, apoptosis and cell cycle distribution via regulating EMT.
Xu H; Zheng JF; Hou CZ; Li Y; Liu PS
Cell Signal; 2019 Oct; 62():109341. PubMed ID: 31176022
[TBL] [Abstract][Full Text] [Related]
33. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract][Full Text] [Related]
35. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
36. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
37. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
39. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
40. Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.
Ahmed N; Greening D; Samardzija C; Escalona RM; Chen M; Findlay JK; Kannourakis G
Sci Rep; 2016 Jul; 6():30061. PubMed ID: 27470985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
